These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 9370178)

  • 21. 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
    Cantarovich M; Durrbach A; Hiesse C; Ladouceur M; Benoit G; Charpentier B
    Transplantation; 2008 Dec; 86(12):1732-7. PubMed ID: 19104413
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized comparison of triple therapy and antithymocyte globulin induction treatment after simultaneous pancreas-kidney transplantation.
    Cantarovich D; Karam G; Giral-Classe M; Hourmant M; Dantal J; Blancho G; Le Normand L; Soulillou JP
    Kidney Int; 1998 Oct; 54(4):1351-6. PubMed ID: 9767555
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, prospective, pharmacoeconomic trial of tacrolimus versus cyclosporine in combination with thymoglobulin in renal transplant recipients.
    Hardinger KL; Bohl DL; Schnitzler MA; Lockwood M; Storch GA; Brennan DC
    Transplantation; 2005 Jul; 80(1):41-6. PubMed ID: 16003231
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients.
    Grimbert P; Baron C; Fruchaud G; Hemery F; Desvaux D; Buisson C; Chopin D; Dahmane D; Remy P; Pastural M; Abbou C; Weil B; Lang P
    Transpl Int; 2002 Nov; 15(11):550-5. PubMed ID: 12461659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mycophenolate mofetil, along with ATG and cyclosporine, significantly lowers the incidence of acute rejection episodes in renal transplant recipients.
    Puig JM; Lloveras J; Fernández-Crespo P; Mir M; Iñigo V; Manresa JM; Masramón J
    Transplant Proc; 1999 Sep; 31(6):2259-60. PubMed ID: 10500567
    [No Abstract]   [Full Text] [Related]  

  • 26. A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft function.
    Hong JC; Kahan BD
    Transplantation; 2001 May; 71(9):1320-8. PubMed ID: 11397971
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil.
    Kimball JA; Pescovitz MD; Book BK; Norman DJ
    Transplantation; 1995 Dec; 60(12):1379-83. PubMed ID: 8545860
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of prophylaxis with low-dose anti-thymocyte globulin on prevention of acute kidney allograft rejection.
    Khosroshahi HT; Tubbs RS; Shoja MM; Ghafari A; Noshad H; Ardalan MR
    Transplant Proc; 2008; 40(1):137-9. PubMed ID: 18261569
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Withdrawal of cyclosporine in renal transplant recipients with acute tubular necrosis improves renal function.
    Kahn D; Botha JF; Pascoe MD; Pontin AR; Halkett J; Tandon V
    Transpl Int; 2000; 13 Suppl 1():S82-3. PubMed ID: 11111968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantation.
    Clark G; Walsh G; Deshpande P; Koffman G
    Nephrol Dial Transplant; 2002 Jul; 17(7):1304-9. PubMed ID: 12105256
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria.
    Morrissey PE; Gohh R; Shaffer D; Crosson A; Madras PN; Sahyoun AI; Monaco AP
    Transplantation; 1997 Mar; 63(6):845-8. PubMed ID: 9089224
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of polyclonal induction agents in pediatric renal transplantation.
    Brophy PD; Thomas SE; McBryde KD; Bunchman TE
    Pediatr Transplant; 2001 Jun; 5(3):174-8. PubMed ID: 11422819
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Low-dose antithymocyte globulins in kidney transplantation: results of a protocol of intermittent administration].
    Mourad G; Portales P; Garrigue V; Djamali A; Bouloux C; Chong G; Clot J
    Nephrologie; 2000; 21(5):253-8. PubMed ID: 11068775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antilymphocyte globulin versus OKT3 induction therapy in cadaveric kidney transplantation: a prospective randomized study.
    Grino JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Mestre M; Torras J; Alsina J
    Am J Kidney Dis; 1992 Dec; 20(6):603-10. PubMed ID: 1462990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunosuppressive properties of the benzothiazepine calcium antagonists diltiazem and clentiazem, with and without cyclosporine, in heterotopic rat heart transplantation.
    Dumont L; Chen H; Daloze P; Xu D; Garceau D
    Transplantation; 1993 Jul; 56(1):181-4. PubMed ID: 8333040
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
    Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
    Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
    [No Abstract]   [Full Text] [Related]  

  • 37. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunosuppressive treatment of primary cadaveric renal transplant patients receiving kidneys from non-heart beating donors.
    Ohshima S; Fujita T; Ono Y; Kinukawa T; Katoh N; Matsuura O
    Artif Organs; 1996 Oct; 20(10):1130-6. PubMed ID: 8896734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
    Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD
    Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction immunosuppressive therapy stratified according to risk categories in renal transplantation.
    Troncoso P; Ortiz AM; Jara A
    Transplant Proc; 2003 Nov; 35(7):2495-9. PubMed ID: 14611995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.